Skip to content
Study details
Enrolling now

Jornay PM Trial

NYU Langone Health
NCT IDNCT06577779ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

30

Study length

about 1 year

Ages

18–60

Locations

1 site in NY

About this study

This trial is testing a treatment called Jornay PM (methylphenidate hydrochloride extended-release capsules) for adult ADHD symptoms. The goal is to see how long this treatment works and if it helps with daytime symptoms, executive function, and emotional regulation.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Methylphenidate Hydrochloride Extended Release Capsule
PhasePhase 4
DrugMethylphenidate Hydrochloride Extended Release Capsule
Routeoral
Primary goalChange in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 10

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 10, Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 3

Secondary: 11-Hours Post-Dose Time-Sensitive ADHD Symptom Scale (TASS) Score at Visit 3, Change from Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score, Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score

Body systems

Psychiatry / Mental Health